Cross-clade immunity in cats vaccinated with a canarypox-vectored avian influenza vaccine

Vaccine

Volumn 28, Issue 31, 2010, Pages 4970-4976

  Stittelaar, Koert J ^a   Lacombe, Valérie ^b   van Lavieren, Rob ^a   van Amerongen, Geert ^a   Simon, James ^a   Cozette, Valérie ^b   Swayne, David E ^c   Poulet, Hervé ^b   Osterhaus, Albert D M E ^a,d  

^a Viroclinics Biosciences BV   (Netherlands)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^c AGRICULTURAL RESEARCH SERVICE   (United States)

^d ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Cat; Clade; H5N1; Influenza; Vaccine

Indexed keywords

AVIAN INFLUENZA VACCINE; HEMAGGLUTINATION INHIBITING ANTIBODY; RECOMBINANT VACCINE; VIRUS HEMAGGLUTININ; VIRUS VECTOR; INFLUENZA VACCINE; VIRUS ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CANARYPOX VIRUS; CAT; CLADISTICS; CONTROLLED STUDY; HEMAGGLUTINATION INHIBITION TEST; HISTOPATHOLOGY; HYPERTHERMIA; INFLUENZA A (H5N1); INFLUENZA VIRUS A H5N1; MORTALITY; NONHUMAN; PRIORITY JOURNAL; PROVOCATION TEST; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK REDUCTION; VACCINATION; VACCINE PRODUCTION; VIRUS DETECTION; VIRUS IMMUNITY; VIRUS LOAD; VIRUS RECOMBINANT; VIRUS SHEDDING; VIRUS TITRATION; VIRUS TRANSMISSION; ANIMAL; ANTIBODY PRODUCTION; BLOOD; CROSS PROTECTION; IMMUNOLOGY; LUNG; ORTHOMYXOVIRIDAE INFECTIONS; PATHOLOGY; PHYSIOLOGY; VETERINARY; VIROLOGY;

ANIMALS; ANTIBODIES, VIRAL; ANTIBODY FORMATION; CANARYPOX VIRUS; CATS; CROSS PROTECTION; HEMAGGLUTINATION INHIBITION TESTS; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; LUNG; ORTHOMYXOVIRIDAE INFECTIONS; VIRUS SHEDDING;

EID: 77954757456     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.05.028     Document Type: Article

References (34)

1. WHO. Cumulative Number of Confirmed Human Cases of Avian Influenza A/(H5N1) Reported to WHO. 31 August 2009 [accessed on 29-September-2009 at ]. http://www.who.int/csr/disease/avian_influenza/country/cases_table_2009_08_31/en/index.html.
2. Thiry E., Zicola A., Addie D., Egberink H., Hartmann K., Lutz H., et al. Highly pathogenic avian influenza H5N1 virus in cats and other carnivores. Vet Microbiol 2007, 122(1-2):25-31.
3. Le M.T., Wertheim H.F., Nguyen H.D., Taylor W., Hoang P.V., Vuong C.D., et al. Influenza A H5N1 clade 2.3.4 virus with a different antiviral susceptibility profile replaced clade 1 virus in humans in northern Vietnam. PLoS One 2008, 3(October (10)):e3339. (Erratum in: PLoS One 2008;3(10). doi:10.1371/annotation/65ab1e39-3b12-4d9d-90e4-905139530448).
4. Kuiken T., Rimmelzwaan G., van Riel D., van Amerongen G., Baars M., Fouchier R., et al. Avian H5N1 influenza in cats. Science 2004, 306(5694):241.
5. Kuiken T., Fouchier R., Rimmelzwaan G., Osterhaus A., Roeder P. Feline friend or potential foe?. Nature 2006, 440(7085):741-742.
6. Poulet H., Minke J., Pardo M.C., Juillard V., Nordgren B., Audonnet J.C. Development and registration of recombinant veterinary vaccines. The example of the canarypox vector platform. Vaccine 2007, 25(30):5606-5612.
7. Plotkin S.A., Cadoz M., Meignier B., Méric C., Leroy O., Excler J.L., et al. The safety and use of canarypox vectored vaccines. Dev Biol Stand 1995, 84:165-170.
8. El Garch H., Minke J.M., Rehder J., Richard S., Edlund Toulemonde C., Dinic S., et al. A West Nile virus (WNV) recombinant canarypox virus vaccine elicits WNV-specific neutralizing antibodies and cell-mediated immune responses in the horse. Vet Immunol Immunopathol 2008, 123(3-4):230-239.
9. Swayne D.E., Senne D.A., Beard C.W. Avian Influenza. A laboratory manual for the isolation and identification of avian pathogens 1998, 150-155. American Association of Avian Pathologists, Kennett Square, PA. 4th ed. D.E. Swayne, J.R. Glisson, M.W. Jackwood, J.E. Pearson, W.M. Reed (Eds.).
10. Kreijtz J.H., Suezer Y., van Amerongen G., de Mutsert G., Schnierle B.S., Wood J.M., et al. Recombinant modified vaccinia virus Ankara-based vaccine induces protective immunity in mice against infection with influenza virus H5N1. J Infect Dis 2007, 195(11):1598-1606.
11. Ruat C., Caillet C., Bidaut A., Simon J., Osterhaus A.D. Vaccination of macaques with adjuvanted formalin-inactivated influenza A virus (H5N1) vaccines: protection against H5N1 challenge without disease enhancement. J Virol 2008, 82(5):2565-2569.
12. Rimmelzwaan G.F., van Riel D., Baars M., Bestebroer T.M., van Amerongen G., Fouchier R.A., et al. Influenza A virus (H5N1) infection in cats causes systemic disease with potential novel routes of virus spread within and between hosts. Am J Pathol 2006, 168(1):176-183.
13. Vahlenkamp T.W., Harder T.C., Giese M., Lin F., Teifke J.P., Klopfleisch R., et al. Protection of cats against lethal influenza H5N1 challenge infection. J Gen Virol 2008, 89(Pt 4):968-974.
14. Klopfleisch R., Wolf P.U., Uhl W., Gerst S., Harder T., Starick E., et al. Distribution of lesions and antigen of highly pathogenic avian influenza virus A/Swan/Germany/R65/06 (H5N1) in domestic cats after presumptive infection by wild birds. Vet Pathol 2007, 44(3):261-268.
15. Leschnik M., Weikel J., Möstl K., Revilla-Fernández S., Wodak E., Bagó Z., et al. Subclinical infection with avian influenza A (H5N1) virus in cats. Emerg Infect Dis 2007, 13(2):243-247.
16. Desvaux S., Marx N., Ong S., Gaidet N., Hunt M., Manuguerra J.C., et al. Highly pathogenic avian influenza virus (H5N1) outbreak in captive wild birds and cats, Cambodia. Emerg Infect Dis 2009, 15(3):475-478.
17. Patel A., Tran K., Gray M., Li Y., Ao Z., Yao X., et al. Evaluation of conserved and variable influenza antigens for immunization against different isolates of H5N1 viruses. Vaccine 2009, 27(23):3083-3089.
18. Paillot R., Kydd J.H., Sindle T., Hannant D., Edlund Toulemonde C., Audonnet J.C., et al. Antibody and IFN-gamma responses induced by a recombinant canarypox vaccine and challenge infection with equine influenza virus. Vet Immunol Immunopathol 2006, 112(3-4):225-233.
19. El Garch H., Richard S., Piras F., Leard T., Poulet H., Andréoni C., et al. Feline leukemia virus (FeLV) specific IFNγ+ T-cell responses are induced in cats following transdermal vaccination with recombinant FeLV vaccine. Int J Appl Res Vet Med 2006, 4(2):100-108.
20. Rimmelzwaan G.F., Sutter G. Candidate influenza vaccines based on recombinant modified vaccinia virus Ankara. Expert Rev Vaccines 2009, 8(4):447-454.
21. Mayrhofer J., Coulibaly S., Hessel A., Holzer G.W., Schwendinger M., Brühl P., et al. Nonreplicating vaccinia virus vectors expressing the H5 influenza virus hemagglutinin produced in modified Vero cells induce robust protection. J Virol 2009, 83(10):5192-5203.
22. Kyriakis C.S., De Vleeschauwer A., Barbé F., Bublot M., Van Reeth K. Safety, immunogenicity and efficacy of poxvirus-based vector vaccines expressing the haemagglutinin gene of a highly pathogenic H5N1 avian influenza virus in pigs. Vaccine 2009, 27(16):2258-2264.
23. Bublot M., Pritchard N., Cruz J.S., Mickle T.R., Selleck P., Swayne D.E. Efficacy of a fowlpox-vectored avian influenza H5 vaccine against Asian H5N1 highly pathogenic avian influenza virus challenge. Avian Dis 2007, 51(1 Suppl.):498-500.
24. Karaca K., Swayne D.E., Grosenbaugh D., Bublot M., Robles A., Spackman E., et al. Immunogenicity of fowlpox virus expressing the avian influenza virus H5 gene (TROVAC AIV-H5) in cats. Clin Diagn Lab Immunol 2005, 12(11):1340-1342.
25. Edlund Toulemonde C., Daly J., Sindle T., Guigal P.M., Audonnet J.C., Minke J.M. Efficacy of a recombinant equine influenza vaccine against challenge with an American lineage H3N8 influenza virus responsible for the 2003 outbreak in the United Kingdom. Vet Rec 2005, 156(12):367-371.
26. Minke J.M., Toulemonde C.E., Coupier H., Guigal P.M., Dinic S., Sindle T., et al. Efficacy of a canarypox-vectored recombinant vaccine expressing the hemagglutinin gene of equine influenza H3N8 virus in the protection of ponies from viral challenge. Am J Vet Res 2007, 68(2):213-219.
27. van der Laan J.W., Herberts C., Lambkin-Williams R., Boyers A., Mann A.J., Oxford J. Animal models in influenza vaccine testing. Expert Rev Vaccines 2008, 7(6):783-793.
28. Barnard D.L. Animal models for the study of influenza pathogenesis and therapy. Antiviral Res 2009, 82(2):A110-A122.
29. Songserm T., Amonsin A., Jam-on R., Sae-Heng N., Meemak N., Pariyothorn N., et al. Avian influenza H5N1 in naturally infected domestic cat. Emerg Infect Dis 2006, 12(4):681-683.
30. Yingst S.L., Saad M.D., Felt S.A. Qinghai-like H5N1 from domestic cats, northern Iraq. Emerg Infect Dis 2006, 12(8):1295-1297.
31. Choi Y.K., Nguyen T.D., Ozaki H., Webby R.J., Puthavathana P., Buranathal C., et al. Studies of H5N1 influenza virus infection of pigs by using viruses isolated in Vietnam and Thailand in 2004. J Virol 2005, 79(16):10821-10825.
32. Lipatov A.S., Kwon Y.K., Sarmento L.V., Lager K.M., Spackman E., Suarez D.L., et al. Domestic pigs have low susceptibility to H5N1 highly pathogenic avian influenza viruses. PLoS Pathog 2008, 4(7):e1000102.
33. van Riel D., Munster V.J., de Wit E., Rimmelzwaan G.F., Fouchier R.A., Osterhaus A.D., et al. H5N1 virus attachment to lower respiratory tract. Science 2006, 312(5772):399.
34. van Riel D., Munster V.J., de Wit E., Rimmelzwaan G.F., Fouchier R.A., Osterhaus A.D., et al. Human and avian influenza viruses target different cells in the lower respiratory tract of humans and other mammals. Am J Pathol 2007, 171(4):1215-1223.